Lung Cancer Trials Ask AI to find trials
WithdrawnPhase 4NCT03167281
Official study title

Early Intrapleural TPA Instillation Versus Late

Study summary

Chest tubes are used for air or fluid removal from the pleural space. When a chest tube is placed, it can be hard for the fluid to drain.Tissue plasminogen activator (tPA) and DNase are given through the chest tube to help with draining the fluid. We are doing this research to see if early addition of tPA-DNase immediately after chest tube placement will help with better fluid draining.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedearly tPA and DNase

The study team can explain what participation involves.

Who it may be forTissue Plasminogen Activator

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 21, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Prisma Health-Midlands

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 4
Sponsor
Prisma Health-Midlands
Interventions being studied
Combination Product: early tPA and DNase
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult patients, age 18 years or older
  • Patients with an indication for a thoracostomy tube placement for a pleural effusion
Reasons someone may not be able to joinExclusion criteria
  • Patients that require a thoracostomy tube for a pneumothorax
  • Pregnant women
  • Sensitivity to t-PA, or DNase
  • Patients taking carbamazepine or nitroglycerin
  • Lung volume reduction surgery on side of pleural effusion

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Palmetto Health RichlandColumbia, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 21, 2025. Always confirm current availability with the study team.

View original record ↗